Veterans face lung cancer as bioAffinity (BIAF) expands test access
Rhea-AI Filing Summary
bioAffinity Technologies, Inc. reported that it entered into a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business that supplies medical and laboratory products to U.S. government agencies. AvMEDICAL’s national sales force will promote bioAffinity’s CyPath® Lung test to federal healthcare customers, including U.S. Department of Veterans Affairs medical centers, using its established procurement channels and indefinite-delivery, indefinite-quantity contracts. The agreement is intended to expand commercial access to CyPath Lung within government healthcare systems and provide an additional pathway for veterans to obtain the test.
CyPath Lung is a noninvasive, laboratory-developed test performed by Precision Pathology Laboratory Services, a wholly owned subsidiary of bioAffinity Technologies. In a published clinical trial of high-risk patients with small indeterminate lung nodules under 20 millimeters, CyPath Lung showed 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value for detecting lung cancer, and is intended for use alongside imaging and other clinical information.
Positive
- None.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
Service-Disabled Veteran-Owned Small Business regulatory
indefinite-delivery, indefinite-quantity (IDIQ) contracts regulatory
Laboratory Developed Test (LDT) medical
flow cytometry technical
negative predictive value (NPV) medical
Clinical Laboratory Improvement Amendments (CLIA) regulatory
FAQ
What distribution agreement did BIAF announce with AvMEDICAL?
How does the AvMEDICAL agreement affect bioAffinity Technologies’ access to VA healthcare markets?
What clinical performance metrics for CyPath Lung does BIAF report?
How is CyPath Lung classified and where is it performed for BIAF?
What lung cancer burden among veterans does BIAF reference in this 8-K?
Does BIAF describe CyPath Lung as a standalone diagnostic for lung cancer?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (I.R.S. Employer | ||
| of incorporation) | File Number) | Identification Number) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||
(Nasdaq Capital Market) | ||||
(Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On August 18, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that it has entered into a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVSB) and established distributor of premium medical and surgical laboratory services, supplies and equipment to government agencies.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
Description | |
| 99.1 | Press Release issued by bioAffinity Technologies, Inc., dated August 18, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |
| -2- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 18, 2026 | BIOAFFINITY TECHNOLOGIES, INC. | |
| By: | /s/ Maria Zannes | |
| Name: | Maria Zannes | |
| Title: | President and Chief Executive Officer | |
| -3- |
Exhibit 99.1
 |
 |
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide
Agreement significantly expands bioAffinity’s commercial reach through AvMEDICAL’s existing sales team
Service-Disabled Veteran-Owned AvMEDICAL provides access to established government procurement channels
SAN ANTONIO, Texas – August 18, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, today announced it has entered into a distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business (SDVOSB) and established distributor of premium medical-surgical and laboratory services, supplies and equipment to government agencies.
The distribution agreement is expected to strengthen bioAffinity’s ability to commercialize CyPath® Lung within the government healthcare market by leveraging AvMEDICAL’s established procurement channels, government contracting expertise and existing customer relationships. bioAffinity and AvMEDICAL will develop co-branded marketing materials, and AvMEDICAL’s sales team will actively promote CyPath Lung to its federal customers, including the U.S. Department of Veteran Affairs (VA).
As an SDVOSB with access to indefinite-delivery, indefinite-quantity (IDIQ) contracts, AvMEDICAL can provide an important advantage for expanding adoption of CyPath Lung across government healthcare systems by simplifying the procurement process. The agreement expands bioAffinity’s commercial reach into the government healthcare supply chain and provides an additional channel for veterans to access CyPath Lung.
“AvMEDICAL’s established presence in the government healthcare marketplace and experienced sales organization will expand our commercial pathway to reach physicians and patients who may benefit from our noninvasive diagnostic to assess lung cancer risk, manage pulmonary nodules and monitor cancer survivorship,” said Maria Zannes, President and CEO of bioAffinity Technologies. “According to the VA, nearly 8,000 veterans are diagnosed with lung cancer and approximately 5,000 will die from the disease annually, making lung cancer a high priority in VA healthcare systems. Early detection is the best way to save lives, and in multiple case studies, CyPath Lung has demonstrated its ability to detect lung cancer as early as curative Stage 1A. We believe working with AvMEDICAL will help us build on our commercial momentum and expand access to CyPath Lung among a vulnerable population.”
“CyPath Lung is a compelling addition to our product portfolio because it meets an unmet need in the diagnostic pathway for lung cancer and can improve patient outcomes among our veterans and active-duty military personnel,” said Troy Mizell, President and CEO of AvMEDICAL. “Our deep understanding of government contracting and the healthcare supply chain will help us deliver greater value to our government customers while expanding access to an innovative technology for the patients they serve.”
CyPath Lung is designed to provide physicians with additional information when evaluating patients with indeterminate pulmonary nodules and may be used in conjunction with imaging and other diagnostic tools. The test is performed by Precision Pathology Laboratory Services (PPLS), a CLIA-certified, CAP-accredited laboratory and a wholly owned subsidiary of bioAffinity Technologies.
About AvMedical
AvMEDICAL is a Service-Disabled Veteran-Owned Small Business (SDVOSB) that sources premium medical-surgical and laboratory supplies and equipment from top-tier manufacturers to the government healthcare system. Since 2020, AvMEDICAL has more than doubled its product portfolio to provide enhanced product offerings to its federal government customers. The portfolio covers key categories, including remote cardiac monitoring, ultrasound, advanced bedside monitors, infusion systems, incontinence products for both hospital and home use, and best-in-class laboratory and respiratory testing solutions.
About CyPath Lung
CyPath Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. CyPath Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. In a published clinical trial of high-risk patients, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV gives physicians greater confidence that a negative result is truly negative, potentially sparing patients from unnecessary invasive and costly procedures. CyPath Lung is marketed as a Laboratory Developed Test (LDT) and is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical Laboratory Improvement Amendments (CLIA), which are administered by the Centers for Medicare & Medicaid Services. For more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully commercialize CyPath Lung through AvMEDICAL’s distribution channels, risks related to government contracting and procurement processes, uncertainties regarding the adoption of CyPath Lung by government healthcare providers, the Company’s reliance on third-party distributors for market access, regulatory developments affecting laboratory developed tests, the Company’s ability to maintain its Nasdaq listing and comply with applicable listing requirements, the Company’s limited operating history and history of losses, and other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Contact
bioAffinity Technologies
Julie Anne Overton
Director of Communications
investors@bioaffinitytech.com